Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its ongoing Phase 1 trial for ADI-001.
Patient enrollment for these cohorts is set to begin in the first quarter of 2025. ADI-001's clinical development now targets six autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
Adicet plans to report initial data from its Phase 1 trial in the first half of 2025.
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
InnoCare receives NMPA approval for orelabrutinib as first-line treatment for CLL/SLL in China
Sanofi invests EUR15m in Innate Pharma to strengthen strategic partnership
Akeso's Ebdarokimab approved in China for moderate-to-severe plaque psoriasis
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases